Alzheimer's disease

The Alzheimer’s Association created a list of early signs of the disease or other types of dementia. In the United States, the disease disproportionately affects Hispanic patients.

Barker died at age 99 from Alzheimer’s disease and other contributing factors, as outlined in his death certificate.

Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients.

Researchers say the finger prick would be quick and non-invasive, and samples could be taken at home, then easily transported for testing.

If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after rival Leqembi. Both drugs pose a serious safety concern — brain swelling and bleeding.

Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.

U.S. health advisers are backing the full approval of an Alzheimer’s drug that received preliminary approval last year. A panel of advisers to the Food and Drug Administration on Friday voted in favor of the infused medication from drugmakers Eisai and Biogen. The FDA granted accelerated approval in January based on early results suggesting the drug could modestly slow Alzheimer’s....

Eli Lilly and Co. said Wednesday its experimental Alzheimer’s drug appeared to slow worsening of the mind-robbing disease in a large study. NBC 5’s Bianca Castro talked with Frisco neurologist Dr. Aimee Garza about how it works.

New data shows an experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening. The next question is how much difference that might make in people’s lives.

Medicare says it’s considering a cut in enrollee premiums, after officials stuck with an earlier decision to sharply limit coverage for a pricey new Alzheimer’s drug projected to drive up program costs